

## *Shilpa Medicare Limited*

### **Corporate & Admin Office:**

“Shilpa House”, # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbshilpa.com, Web: www.vbshilpa.com  
CIN: L85110KA1987PLC008739

Date: 16<sup>th</sup> September, 2022

Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400001

National Stock Exchange of India Limited  
Exchange Plaza, 05th Floor,  
Plot No: C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400051

**Sub: Intimation U/R 30 of the SEBI (LODR) Regulations 2015- Reg.**

**Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

\*\*\*\*\*

Dear Sir / Madam,

This is to inform you that the Company has received U.S Food and Drug Administration tentative approval for its ANDA, Tenofovir Alafenamide Tablets, 25 mg on 15 Sep 2022. The ANDA was filed as ‘First to File’ submission on NCE -1 date.

Tenofovir Alafenamide Tablets, 25 mg is a generic equivalent of reference listed drug (RLD) Vemlidy® tablets, of Gilead Sciences Inc. used in the treatment of chronic hepatitis B virus infection as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2022 data, the US market for Tenofovir Alafenamide Tablets, 25 mg is approximately US\$ 498.14 Million.

This is for your information and doing the needful.

For **SHILPA MEDICARE LIMITED**

**Ritu Tiwary**  
**Company Secretary & Compliance Officer**